Using Trademarks to Ensure Completion of Postapproval Trials

The FDA should use trademarks to ensure the timely completion of postapproval confirmatory trials for drugs granted accelerated approval . Manufacturer use of a drug’s trademarked brand or generic name should be restricted until trials confirm clinical benefit, instead requiring investigational names in promotional materials to communicate the drug’s clinical uncertainty.